Most Read Articles
20 May 2019

Dr Michael Lim, a senior consultant at the Paediatric Pulmonary and Sleep Division, National University Hospital, Singapore, speaks to Roshini Claire Anthony on the rare disease that is cystic fibrosis.

31 May 2019
Co-therapy with proton pump inhibitors (PPIs) in patients receiving low-dose anticoagulation and/or aspirin for stable cardiovascular disease confers no benefit for upper gastrointestinal events but may reduce bleeding due to gastroduodenal lesions, a study has shown.
Laura Kho Sui San , 29 May 2019
Anxiety becomes a pathological disorder when it occurs for no detectable reason, persists and interferes with daily activities like work performance and relationships.
Jairia Dela Cruz, 10 Jun 2019
Statins appear to exert neuroprotective effects in diabetic prostate cancer patients receiving androgen deprivation therapy (ADT), with a recent study showing that the drug confers benefit for the risk of dementia. The benefit is greater with higher statin adherence and intensity.

Gentamicin exposure in the NICU does not affect hearing screen results

31 Dec 2018
The Kangaroo Mother Care (KMC) idea, which originated amid grinding poverty, may be a cheaper and better option than incubators in saving premature babies.

Gentamicin treatment in infants, regardless of dosing or duration, does not affect the risk of failing a hearing screen at the time of discharge from the neonatal intensive care unit (NICU), a recent study has found.

The study included 84,808 infants who received gentamicin in the first 120 days of life, of whom 15 percent (n=12,593) were born very low birth weight (VLBW). Participants received an average daily dose of 3.8 mg/kg/day. The cumulative dose received and median duration of exposure was 12.1 mg/kg and 3 days, respectively.

The median cumulative daily dose received was significantly higher in those who failed than in those who passed (15.26 vs 12.08 mg/kg), though there was no difference in the highest daily dose administered (3.98 vs 3.96 mg/kg; p=0.21).

Of the participants, only 3.8 percent (n=3,238) failed the hearing screen. Multivariable adjusted logistic regression analysis showed that gentamicin exposure, measured as the average daily dose (odds ratio [OR], 1.01; 95 percent CI, 0.98–1.05; p=0.46), had no significant impact on the risk of failing the hearing screen.

The findings held true when exposure was measured as cumulative dose (OR, 1.00; 1.00–1.00; p=0.07), highest daily dose (OR, 0.99–1.05; p=0.20) and duration of exposure (OR, 1.01; 1.00–1.02; p=0.10).

A subgroup analysis on VLBW similarly showed that gentamicin exposure had generally no impact on hearing screen results (average daily dose: OR, 1.02; 0.97–1.07; p=0.54; highest daily dose: HR, 1.03; 0.99–1.07; p=0.13; duration of exposure: OR, 1.01; 0.99–1.02; p=0.26), except for when measured cumulative dose, though the magnitude of effect was minimal (OR, 1.00; 1.00–1.01; p=0.03).

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
20 May 2019

Dr Michael Lim, a senior consultant at the Paediatric Pulmonary and Sleep Division, National University Hospital, Singapore, speaks to Roshini Claire Anthony on the rare disease that is cystic fibrosis.

31 May 2019
Co-therapy with proton pump inhibitors (PPIs) in patients receiving low-dose anticoagulation and/or aspirin for stable cardiovascular disease confers no benefit for upper gastrointestinal events but may reduce bleeding due to gastroduodenal lesions, a study has shown.
Laura Kho Sui San , 29 May 2019
Anxiety becomes a pathological disorder when it occurs for no detectable reason, persists and interferes with daily activities like work performance and relationships.
Jairia Dela Cruz, 10 Jun 2019
Statins appear to exert neuroprotective effects in diabetic prostate cancer patients receiving androgen deprivation therapy (ADT), with a recent study showing that the drug confers benefit for the risk of dementia. The benefit is greater with higher statin adherence and intensity.